Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-09

Clinical Trial Update: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update for AMG 334 in adults with episodic migraine reports results; completed study with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMG 334 (erenumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-03-09